Summer Sale
50% off Premium Yearly
TSE:GUD
Knight Therapeutics (GUD.TO)
Financials 
Technical Analysis 
Jun 22, 2026, 12:00 amThis summary was created by AI, based on 3 opinions in the last 12 months.
Knight Therapeutics (GUD-T) currently stands at a crucial juncture, with varying perspectives from experts. While one expert highlights its value proposition, considering the market's demand for consistent earnings amidst the company's strategy of acquiring 'orphaned' drugs, there is skepticism about its ability to consistently deliver results. Another expert acknowledges the potential for long-term investment, although they caution that the stock's erratic performance may lead to frustrations among investors, as evident from the recent fluctuations around the $5.75-6 mark. The chart's current state indicates that unless support levels are maintained, the share price could retreat towards $5.14. Despite the presence of promising indicators, the consensus underscores the necessity for patience and possibly exploring other avenues in the increasingly intriguing healthcare sector. Furthermore, the company's performance in terms of revenue and operational margins, particularly in Brazil, suggests that there are positive developments afoot, yet the path to consistent gains may require continued endurance.
Fits and starts, always lots of promise. Good management, but stock never quite delivers. Right now lots of chop on the chart, so the market's trying to hold at current levels of $5.75-6. If it can't hold, will probably head back down to $5.14. A lot of the technical indicators are oversold, but justice is not guaranteed by it going back up.
You have to decide if you want to ride it out or go elsewhere. Healthcare is getting interesting. See his Top Picks.
Shares are flat, but the company has done well the past 12 months. Topline is doing well as are Brazil operations. Margins are expanding. You need patience.
Andrey Omelchak
(Note the short timeframe.)
One of the cheapest small caps, accumulate on weakness. Pullback gives you the opportunity. Good job setting stage for margin improvement over time, not overnight. High net-cash position. Capital discipline, good insider ownership.
Andrey OmelchakA hidden gem. Low liquidity, but has good topline growth, strong margin expansion potential and the CEO has a great track record from Paladin Labs. It buys existing drug platforms, and can now leverage that platform to introduce new drug therapies. Huge net cash and keep buying back shares.
(Analysts’ price target is $7.60)Andrey OmelchakThe stock is acting better, and is up 15% YTD. It has been a while since it saw $6. EPS was -4c vs expectations of (nil). Revenue was $86.6M, beating estimates of $83.1M. EBITDA of $13.58M missed estimates of this $14.47M. Guidance was largely maintained. Revenue rose 4.9%, with margins a bit higher than estimates. Net cash is about $90M. Still not much excitement here. Some recent partnerships look more interesting than the quarterly results. It is good to see the sales gain, but we would not yet call this a dramatic turn.
Unlock Premium - Try 5i Free
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Trades at a cheap valuation. Investors’ patience has run out. Recent acquisition gave it a new life. Current environment can be favorable. Unlock Premium - Try 5i Free
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Knight Therapeutics (GUD.TO) Frequently Asked Questions
What is Knight Therapeutics stock symbol?
Knight Therapeutics is a Canadian stock, trading under the symbol GUD.TO (previously GUD-T on Stockchase) on the Toronto Stock Exchange (GUD-CT). It is usually referred to as TSX:GUD or GUD.TO
Is Knight Therapeutics a buy or a sell?
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on GUD.TO (previously GUD-T on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is WAIT. Read the latest stock experts' ratings for Knight Therapeutics.
Is Knight Therapeutics a good investment or a top pick?
Knight Therapeutics was recommended as a Top Pick by Jason Mann on 2021-09-07. Read the latest stock experts ratings for Knight Therapeutics.
Why is Knight Therapeutics stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Knight Therapeutics.
Is Knight Therapeutics worth watching?
Knight Therapeutics is followed by 135 investors on Stockchase and is a trending stock that is worth watching.
What is Knight Therapeutics stock price?
On 2026-06-19, Knight Therapeutics (GUD.TO) stock closed at a price of $9.27.
Value here. Market's looking for better consistency on earnings so it can keep on with its business model of buying "orphaned" drugs. On his radar because it's cheap.